Hepatitis B and liver transplantation

Sandeep Mukherjee, Urmila Mukherjee

Research output: Contribution to journalReview article

Abstract

Liver transplantation was approved for the treatment of decompensated cirrhosis in the United States in 1983. Hepatitis B and hepatitis C viruses are the leading causes of liver transplantation for viral hepatitis and hepatitis B is also an important cause of liver transplantation for fulminant liver failure (also called acute liver failure) due to either acute hepatitis B or an acute exacerbation of chronic hepatitis B. However, until the introduction of hepatitis B immunoglobulin and nucleoside/nucleotide analogues nearly twenty years ago, liver transplantation for hepatitis B was characterized by universal recurrence with a dismal prognosis. At present, liver transplantation for hepatitis B, regardless of whether for decompensated cirrhosis, hepatocellular carcinoma satisfying Milan criteria or acute liver failure has excellent outcomes with results comparable if not better to other liver transplant recipients. This article will review the management of patients with decompensated cirrhosis from HBV prior to liver transplantation, the use of hepatitis B positive donors and the prevention and management of hepatitis B after liver transplantation.

Original languageEnglish
Pages (from-to)194-201
Number of pages8
JournalCurrent Drug Therapy
Volume4
Issue number3
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Hepatitis B
Liver Transplantation
Acute Liver Failure
Fibrosis
Chronic Hepatitis B
Nucleosides
Hepacivirus
Hepatitis
Immunoglobulins
Hepatocellular Carcinoma
Nucleotides
Tissue Donors
Recurrence
Liver

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Hepatitis B and liver transplantation. / Mukherjee, Sandeep; Mukherjee, Urmila.

In: Current Drug Therapy, Vol. 4, No. 3, 09.2009, p. 194-201.

Research output: Contribution to journalReview article

Mukherjee, Sandeep ; Mukherjee, Urmila. / Hepatitis B and liver transplantation. In: Current Drug Therapy. 2009 ; Vol. 4, No. 3. pp. 194-201.
@article{b46fcff1189040dd84ca6aba86b58cb2,
title = "Hepatitis B and liver transplantation",
abstract = "Liver transplantation was approved for the treatment of decompensated cirrhosis in the United States in 1983. Hepatitis B and hepatitis C viruses are the leading causes of liver transplantation for viral hepatitis and hepatitis B is also an important cause of liver transplantation for fulminant liver failure (also called acute liver failure) due to either acute hepatitis B or an acute exacerbation of chronic hepatitis B. However, until the introduction of hepatitis B immunoglobulin and nucleoside/nucleotide analogues nearly twenty years ago, liver transplantation for hepatitis B was characterized by universal recurrence with a dismal prognosis. At present, liver transplantation for hepatitis B, regardless of whether for decompensated cirrhosis, hepatocellular carcinoma satisfying Milan criteria or acute liver failure has excellent outcomes with results comparable if not better to other liver transplant recipients. This article will review the management of patients with decompensated cirrhosis from HBV prior to liver transplantation, the use of hepatitis B positive donors and the prevention and management of hepatitis B after liver transplantation.",
author = "Sandeep Mukherjee and Urmila Mukherjee",
year = "2009",
month = "9",
doi = "10.2174/157488509789054983",
language = "English",
volume = "4",
pages = "194--201",
journal = "Current Drug Therapy",
issn = "1574-8855",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Hepatitis B and liver transplantation

AU - Mukherjee, Sandeep

AU - Mukherjee, Urmila

PY - 2009/9

Y1 - 2009/9

N2 - Liver transplantation was approved for the treatment of decompensated cirrhosis in the United States in 1983. Hepatitis B and hepatitis C viruses are the leading causes of liver transplantation for viral hepatitis and hepatitis B is also an important cause of liver transplantation for fulminant liver failure (also called acute liver failure) due to either acute hepatitis B or an acute exacerbation of chronic hepatitis B. However, until the introduction of hepatitis B immunoglobulin and nucleoside/nucleotide analogues nearly twenty years ago, liver transplantation for hepatitis B was characterized by universal recurrence with a dismal prognosis. At present, liver transplantation for hepatitis B, regardless of whether for decompensated cirrhosis, hepatocellular carcinoma satisfying Milan criteria or acute liver failure has excellent outcomes with results comparable if not better to other liver transplant recipients. This article will review the management of patients with decompensated cirrhosis from HBV prior to liver transplantation, the use of hepatitis B positive donors and the prevention and management of hepatitis B after liver transplantation.

AB - Liver transplantation was approved for the treatment of decompensated cirrhosis in the United States in 1983. Hepatitis B and hepatitis C viruses are the leading causes of liver transplantation for viral hepatitis and hepatitis B is also an important cause of liver transplantation for fulminant liver failure (also called acute liver failure) due to either acute hepatitis B or an acute exacerbation of chronic hepatitis B. However, until the introduction of hepatitis B immunoglobulin and nucleoside/nucleotide analogues nearly twenty years ago, liver transplantation for hepatitis B was characterized by universal recurrence with a dismal prognosis. At present, liver transplantation for hepatitis B, regardless of whether for decompensated cirrhosis, hepatocellular carcinoma satisfying Milan criteria or acute liver failure has excellent outcomes with results comparable if not better to other liver transplant recipients. This article will review the management of patients with decompensated cirrhosis from HBV prior to liver transplantation, the use of hepatitis B positive donors and the prevention and management of hepatitis B after liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=73449089455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449089455&partnerID=8YFLogxK

U2 - 10.2174/157488509789054983

DO - 10.2174/157488509789054983

M3 - Review article

VL - 4

SP - 194

EP - 201

JO - Current Drug Therapy

JF - Current Drug Therapy

SN - 1574-8855

IS - 3

ER -